SMM Global – Stock Market Manager Stock Market Manager simplifies distribution and disclosure of press releases, research and corporate news to financial terminals, print, broadcast and trade media, wire services, news agencies, databases, portals and websites.
Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals Holding Corp. engages in developing medicines for common disorders of the central nervous system. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. The company’s lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of fibromyalgia; and Phase II clinical stage for the treatment of post-traumatic stress disorder. It also engages in developing TNX-301, a fixed dose combination drug product that contains disulfiram and selegiline for the treatment of alcohol use disorders, as well as biodefense development programs for protection from smallpox virus and radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is headquartered in New York, New York.
Description
Tonix Pharmaceuticals Holding Corp. engages in developing medicines for common disorders of the central nervous system. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. The company’s lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of fibromyalgia; and Phase II clinical stage for the treatment of post-traumatic stress disorder. It also engages in developing TNX-301, a fixed dose combination drug product that contains disulfiram and selegiline for the treatment of alcohol use disorders, as well as biodefense development programs for protection from smallpox virus and radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is headquartered in New York, New York.
Contact Information
509 Madison Avenue
Suite 306
New York, NY 10022
Financial Reporting/Disclosure
Reporting Status : U.S. Reporting: SEC Reporting
Latest Report : Mar 31, 2016 10-Q
CIK : 0001430306
Fiscal Year End : 12/31
OTC Marketplace : Not Available
Profile Data
SIC – Industry Classification : Not Available
Incorporated In : NV, USA
Year of Inc. : Not Available
Employees : Not Available
Company Officers/Contacts
Dr. Seth Lederman M.D. ┃ Co-Founder, Chairman, and Chief Exec. Officer
Dr. Donald W. Landry M.D., Ph.D. ┃ Co-Founder and Director
Mrs. Jessica Edgar Morris ┃ Exec. VP of Operations
Dr. Bruce L. Daugherty Ph.D., M.B.A. ┃ Chief Scientific Officer, Controller and Sec.
Dr. Gregory M. Sullivan M.D. ┃ Chief Medical Officer
Service Providers
Accounting/Auditing Firm
EisnerAmper LLP
750 Third Avenue
New York, NY, 10017
United States
Legal Counsel
Sichenzia Ross Friedman Ference LLP
61 Broadway
32nd Floor
New York, NY, 10006
United States
Investor Relations Firm
Lippert/Heilshorn & Associates
800 Third Avenue
17th Floor
New York, NY, 10022
United States
Company Notes
- Formerly=Tamandare Explorations, Inc. until 10-2011